Drug Trial Radar · NCT06216938
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Mar 7, 2024
Primary completion
Mar 31, 2028
Study completion Mar 31, 2029
Sponsor
- Lead sponsor
- Yana NajjarAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Replimune, Inc.
- First posted
- Jan 22, 2024
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This early-phase study will examine Vusolimogene Oderparepvec, a genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities. Upon administration, vusolimogene oderparepvec specifically targets, infects and replicates in tumor cells and does not infect healthy cells. This results in tumor cell lysis and the release of virus particles which infect and replicate within nearby tumor cells, resulting in tumor cel death. The immune system is activated by the released tumor-associated antigens (TAAs) from the tumor cells creating an anti-tumor immune response against the tumor cells, thereby further killing the tumor cells. The virus itself also elicits a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells.
Conditions
- Melanoma
Interventions
Vusolimogene oderparepvec (RP1)Biological
Vusolimogene Oderparepvec is a genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Sentinel Lymph Node (SLN) PositivityTime frame: Up to 2 years (cohort)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.